Blog

July 2022 Publications

By JWoolley | August 10, 2022

A compilation of articles related to TB vaccine R&D published in July 2022

Read More...

June 2022 Publications

By WGNV | July 13, 2022

A compilation of articles related to TB vaccine R&D published in June 2022.

Read More...

May 2022 Publications

By WGNV | June 6, 2022

A compilation of articles related to TB vaccine R&D published in May 2022.

Read More...

April 2022 Publications

By WGNV | May 10, 2022

A compilation of articles related to TB vaccine R&D published in April 2022.

Read More...

Looking at the Future of TB Research as an Early Career Researcher

By Ryan M. Kane, MD, MPH & Hunter Spencer, DO | April 18, 2022

Despite the discovery of the causative agent of tuberculosis (TB) (Mycobacterium tuberculosis) by Robert Koch in 1882, there are still many questions regarding the pathophysiology of TB that remain unanswered—particularly in the differentiation and marked variability between latent (asymptomatic, non-transmissible) and active (symptomatic, transmissible) stages of infection. In 2020 the World Health Organization (WHO) estimated…

Read More...

March 2022 Publications

By WGNV | March 12, 2022

A compilation or articles related to TB vaccine R&D published in March 2022

Read More...

February 2022 Publications

By WGNV | March 4, 2022

A compilation of articles related to TB vaccine R&D published in February 2022.

Read More...

January 2022 Publications

By WGNV | March 4, 2022

A compilation of articles related to TB vaccine R&D published in January 2022.

Read More...

TB advocates call on Europe to fulfil commitments for new TB vaccines

By Shaun Palmer | February 17, 2022

As representatives of communities affected by tuberculosis (TB) – including survivors, researchers and civil society organizations – we demand long overdue global investments in the research and development of new TB vaccines commensurate with the disease’s devastating impact. The sixth Global Forum on TB Vaccines will be virtually hosted by Toulouse, France this February 22–25…

Read More...

Leveraging COVID-19 public-private partnerships for TB vaccine development

By Ryan M. Kane, MD, MPH & Hunter Spencer, DO | February 8, 2022

The past few years have created a paradigm shift in the way we globally respond to and address communicable diseases. Though we remain in the midst of the COVID-19 pandemic, several novel vaccine candidates have been developed, manufactured, studied, approved, distributed, and administered to millions of individuals around the world in less than one year.…

Read More...

Guest posts published on this blog reflect the views of their authors and persons interviewed and do not necessarily reflect the views of the Stop TB Partnership Working Group on New TB Vaccines.